Navigation Links
TaiGen Amends Global License Agreement with Warner Chilcott plc for Development and Commercialization of Nemonoxacin -- a New Generation Quinolone Antibiotic

TaiGen Amends Global License Agreement with Warner Chilcott plc for Development and Commercialization... -- TAIPEI, Taiwan, Oct. 14 /PRNewswire-Asia/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Pharmaceuticals, Licensing Click to view news release full screen  

TaiGen Amends Global License Agreement with Warner Chilcott plc for Development and Commercialization of Nemonoxacin -- a New Generation Quinolone Antibiotic


TAIPEI, Taiwan, Oct. 14 /PRNewswire-Asia/ -- TaiGen Biotechnology Co., Ltd. today announced that TaiGen has entered into an amendment to its license agreement with Warner Chilcott plc regarding the development and commercialization of nemonoxacin -- a new generation quinolone antibiotic.

Under the terms of the original license agreement, entered into in December 2004, TaiGen licensed exclusive development, manufacture and commercialization rights to nemonoxacin from The Procter & Gamble Company in mainland China, Hong Kong, Taiwan, South Korea and certain other Asian countries, and assumed responsibility, at its sole cost and expense, for the conduct of a Phase Ib study and two Phase II trials in community-acquired bacterial pneumonia (CABP) and diabetic foot infection (DFI) patients, respectively, in which nemonoxacin demonstrated an excellent efficacy and safety profile. Upon Warner Chilcott's purchase of the global branded pharmaceuticals business of Procter & Gamble in October 2009, Warner Chilcott assumed Procter & Gamble's interest in the license agreement.

Under the terms of the amended agreement, entered into following the conclusion of Phase II trials, TaiGen keeps its exclusive development, manufacture and commercialization rights to nemonoxacin in the countries under the original license agreement, while Warner Chilcott retains development and commercialization rights in all other markets, including the United States and Europe. TaiGen and Warner Chilcott have agreed to cross-license their respective patent rights relating to nemonoxacin and TaiGen will transfer to Warner Chilcott its Investigational New Drug Application filed with the FDA. Upon the execution of the amended agreement, TaiGen received an upfront payment from Warner Chilcott and is eligible for certain regulatory milestone payments, as well as a royalty based on Warner Chilcott's net sales of the product.

Warner Chilcott plc is a leading specialty pharmaceutical company currently focused on the gastroenterology, women's healthcare, dermatology and urology segments of the North American and Western European pharmaceuticals markets.

"We are very encouraged by the signing of the amended agreement with Warner Chilcott," said Dr. Ming-Chu, Hsu, Chairman and CEO of TaiGen. "The deal proved TaiGen's capabilities in conducting clinical and regulatory development with high quality and at standards set by the United States Food and Drug Administration (US FDA). It also validated TaiGen's business model of building R&D portfolio through both internal R&D and external collaboration and licensing."

With China being a fast growing pharmaceutical market, TaiGen, which set up its Beijing affiliate in 2005, has been developing nemonoxacin under the China SFDA (China State Food and Drug Administration) regulation. It is expected that nemonoxacin will enter Phase III development in China very soon.

About TaiGen Biotechnology

TaiGen Biotechnology ( ) is a leading development stage pharmaceutical company based in Taiwan with a wholly-owned subsidiary in Beijing, China. The company has a full capacity in discovery research and clinical development in mainland China/Taiwan/US. Its current pipeline includes therapeutics for infectious diseases, diabetic complications and cancer for the worldwide market.

Media Contacts: Dr. John Jin Vice President for Business Development Tel: +886-2-8177-7072 Email:

SOURCE TaiGen Biotechnology Co., Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
2. TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting
3. TaiGen Announces Nemonoxacin (TG-873870) Once-A-Day Oral Dosing in Diabetic Foot Infection Met Primary Endpoints
4. KV Pharmaceutical Amends Agreement to Secure Rights to Gestiva(TM)
5. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
6. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
7. Directors Forum: PEPFAR and the Global AIDS Response
8. Alfacell Corporation to Present at UBS Global Life Sciences Conference
9. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
10. Global HIV Vaccine Enterprise Names Alan Bernstein as Inaugural Executive Director, Opens New Secretariat
11. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
Post Your Comments:
(Date:11/26/2015)... -- 3D bioprinting market is expected to ... report by Grand View Research Inc. Rising prevalence of chronic ... transplantation is expected to boost the market growth, as 3D ... --> 3D bioprinting market is expected to ... report by Grand View Research Inc. Rising prevalence of chronic ...
(Date:11/26/2015)... , November 26, 2015 ... addition of the "2016 Future Horizons ... of Abuse Testing Market: Supplier Shares, Country ... report to their offering. --> ... the "2016 Future Horizons and Growth ...
(Date:11/26/2015)... , November 26, 2015 ... of the "2016 Future Horizons and ... Abuse Testing Market: Supplier Shares, Country Segment ... to their offering. --> ... "2016 Future Horizons and Growth Strategies ...
Breaking Medicine Technology:
(Date:11/28/2015)... ... November 28, 2015 , ... Beginning November 30th at 6:00 a.m. EST until 11:59 ... savings. , With possible savings of up to 20% off orders $80 or more to ... the website every few hours. , As a competitive e-commerce website for skin care and ...
(Date:11/27/2015)... CA (PRWEB) , ... November 27, 2015 , ... According ... at the recent 2015 American Dental Association meeting in Washington D.C. revolved around the ... protect a patient’s overall health. The talk stressed the link between periodontal disease (more ...
(Date:11/27/2015)... ... November 27, 2015 , ... The rapid speed ... As people age, more care is needed, especially with Alzheimer’s, dementia and other ... are being overworked. The forgotten part of this equation: 80 percent of medical ...
(Date:11/27/2015)... ... November 27, 2015 , ... "When I was traveling, ... from Hillside, N.J. "Many people catch diseases simply from sitting on such dirty ... be protected from germs." , He developed the patent-pending QUDRATECS to eliminate the ...
(Date:11/27/2015)... ... ... ProSidebar: Fashion is a set of 30 kinetic edge graphics ... editors can easily add an informative sidebar to any FCPX production. Create lists, ... self-animating drop zones, lines, bars, and text with the ease of FCPX's drag and ...
Breaking Medicine News(10 mins):